NIKA PHARMACEUTICALS, INC (NIKA) stock: key figures, P/E, revenue and dividend
Health Care · United States
NIKA PHARMACEUTICALS, INC financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -76,398.00 USD |
| EBIT | -76,398.00 USD |
| Net income | -76,398.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NIKA PHARMACEUTICALS, INC
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
More stocks
- Beijing Hanbang Technology Corp (300449.SZ)
- KAISA JiaYun Technology Inc (300242.SZ)
- Inland Real Estate Income Trust, Inc. (INRE)
- Braiin Limited Common Stock (BRAI)
- Cabral Gold Inc (CBR.V)
- Shan Dong Delisi Food Co Ltd (002330.SZ)
- Nanjing TDH Technology Co. Ltd. A (301378.SZ)
- Energiekontor (EKT.DE)
- Elma Electronic AG (ELMN.SW)
- Global IBO Group Ltd (GIBO)
- Elite Color Environmental Resources (002998.SZ)
- KENGIC Intelligent Technology Co. Ltd. A (688455.SS)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.